Research & Validation

Evidence base: published literature, cited and verified. Validation studies: designed, IRB-gated.

Abstract

This research began before the first line of code. As a licensed clinician learning to build software, the author investigated medication-related deaths and the evidence base behind current care, and those findings shaped every design decision in the FSL system. The work addresses five problems in mental-wellness education: stigma, shame, access, privacy and autonomy. It asks whether a wallet-signed, participant-controlled system can lower barriers to help-seeking while keeping consent verifiable and revocable. Six research streams organize the evidence: stigma and access; participant autonomy and data sovereignty; privacy and consent; orthomolecular and neurobiological evidence; informatics and interoperability; and decentralized architecture. The planned study designs are a randomized comparison of entry flows, within-subject consent-comprehension testing, formal protocol verification, an IRB-gated observational cohort, FHIR conformance testing and operational measurement. The doctoral contribution specifies bilateral wallet-signed consent: the participant and the Sovereign Guide each sign, and session keys are designed to derive from both signatures, so that a session can only be established with both parties’ consent.

Doctoral thesis: “Bilateral Wallet-Signed Consent: A Custom Signature Protocol for Decentralized Sovereign Data Governance, with Behavioral Health as Proving Ground.” Central research question: Can wallet-signed bilateral consent serve as a defensible governance primitive for sovereign behavioral health data? Full scope: Doctoral Scope.

The Problem in Numbers

157,149,246

people live in designated Mental Health Professional Shortage Areas (as of June 30, 2026).

Source: HRSA, 2026, HPSA quarterly report, Table 1, p. 2

96.3%

of people with a 12-month DSM-IV disorder who perceived a need and did not seek treatment reported an attitudinal barrier (24 countries, n = 4,583).

Source: Andrade et al., 2014, Table 3

290,054,222

individuals affected, reported as a combined total by the 741 breach filings affecting 500 or more individuals submitted to HHS in 2024 (portal tally, Sept 30, 2026).

Source: HHS OCR breach portal

52.1%

of trial participants understood randomization, the least-understood consent component (103 studies).

Source: Tam et al., 2015

Data and code: rv-evidence.csv · build-rv-charts.py (every figure in the charts comes from this file; the script regenerates the charts deterministically) · ocr-breach-export-2026-09-30.csv (the HHS OCR breach portal export behind the breach figures, taken 2026-09-30; SHA-256 a05a0eb2dcff81c316fcce9ff0e5683e49ea806a0cb448999cd25edc09e92084).

Research Questions and Hypotheses

StreamResearch questionHypothesis (Planned)Doctoral lane
Stigma and AccessCan an education entry point that asks for no name or disclosure, only a wallet signature, reduce the disclosure and attitudinal barriers that deter help-seeking for mental wellness?Participants who enter through the wallet-signature entry point report lower BACE treatment-stigma subscale scores than participants who enter through a name-and-email registration.VALIDATE
Participant Autonomy and Data SovereigntyCan participants hold cryptographic proof of each grant and revocation of access to their wellness records, so that consent is demonstrable and as easy to withdraw as to give?Participants who grant and revoke access with wallet signatures identify who can read their records and how to withdraw access at QuIC objective-understanding scores non-inferior to those after a conventional consent form (margin: 5 points on the 0–100 QuIC scale).VALIDATE
Privacy and ConsentCan wallet signatures bound to single-use nonces yield sign-in and consent records that cannot be replayed, and what does EIP-712 domain separation add beyond EIP-191?The nonce-bound EIP-191 sign-in and consent protocols satisfy replay resistance and authentication properties against a network attacker, and an EIP-712 variant adds a domain binding that the EIP-191 model lacks.PROVE
Orthomolecular and Neurobiological EvidenceWhich participants respond to specific evidence-based nutrients and plant-based and gluten-free dietary change, and can participant-held longitudinal self-report make that individual response observable?Participant-reported mood trajectories over 12 weeks differ between participants who adopt an evidence-based nutrient or a plant-based and gluten-free dietary change and those who do not, with individual response varying across participants. Primary contrast: plant-based dietary change, consistent with the meta-analytic evidence that dietary improvement reduces depressive symptoms (Firth et al., 2019b); gluten-free adherence is a pre-specified exploratory moderator, because the evidence for gluten-free diets and mood is limited to people with gluten-related disorders (Busby et al., 2018).VALIDATE
Informatics and InteroperabilityCan device and laboratory results reach a participant-controlled record as standard FHIR R4 resources, with access governed by the participant’s own signed consent?Device and laboratory data mapped by the FSL pipelines pass FHIR R4 validation and preserve every source value, unit and code.VALIDATE
Decentralized ArchitectureCan a small clinical practice operate decentralized payment and record-integrity infrastructure in production, a self-hosted Bitcoin node with a watch-only wallet and Merkle roots anchored to a public chain, and verify it end to end?The self-hosted payment and anchoring stack records every settled payment exactly once and verifies every anchored record against its on-chain root.BUILD

Stigma and Access

Feeds: VALIDATE

Evidence

People’s own negative attitudes toward help-seeking (OR 0.80) and stigmatising attitudes (OR 0.82) are associated with less help-seeking while perceived public stigma is not (OR 0.97, 95% CI 0.93–1.02; Schnyder et al., 2017); among people with a 12-month DSM-IV disorder who perceived a need and did not seek treatment, 96.3% reported an attitudinal barrier against 22.6% for any structural barrier, and 157,149,246 people live in designated mental health shortage areas.

Stigma and active help-seeking (odds ratios, 95% CI)
Stigma and active help-seeking (odds ratios, 95% CI)

Source: Schnyder et al., 2017, 27 studies, n = 31,677

View data
ItemValue95% CInSource
Own negative help-seeking attitudes0.80 (OR)0.73 to 0.8827 studies; 31,677 participants (review total)Schnyder et al., 2017
Stigmatising attitudes (personal stigma)0.82 (OR)0.69 to 0.9827 studies; 31,677 participants (review total)Schnyder et al., 2017
Self-stigma0.88 (OR)0.76 to 1.0327 studies; 31,677 participants (review total)Schnyder et al., 2017
Perceived public stigma0.97 (OR)0.93 to 1.0227 studies; 31,677 participants (review total)Schnyder et al., 2017
General stigma (unspecified)0.98 (OR)0.84 to 1.1527 studies; 31,677 participants (review total)Schnyder et al., 2017
Reasons for not seeking treatment among people with a 12-month disorder who perceived a need
Reasons for not seeking treatment among people with a 12-month disorder who perceived a need

Source: Andrade et al., 2014, WHO World Mental Health surveys, 24 countries, n = 4,583 (Table 3)

View data
ItemValue95% CInSource
Any attitudinal barrier96.3%—4,583Andrade et al., 2014
Wanted to handle the problem on their own63.8%—4,583Andrade et al., 2014
Problem was not severe24.4%—4,583Andrade et al., 2014
Any structural barrier22.6%—4,583Andrade et al., 2014
Thought it would get better16.0%—4,583Andrade et al., 2014
Financial15.9%—4,583Andrade et al., 2014
Perceived ineffectiveness15.7%—4,583Andrade et al., 2014
Availability12.4%—4,583Andrade et al., 2014
Stigma7.7%—4,583Andrade et al., 2014
Inconvenient6.4%—4,583Andrade et al., 2014
Transportation5.4%—4,583Andrade et al., 2014
Mental Health HPSA designations by type, June 30, 2026
Mental Health HPSA designations by type, June 30, 2026

Source: HRSA, 2026, HPSA quarterly report as of June 30, 2026, Table 1

View data
ItemValue95% CInSource
Facility designations4,925——HRSA, 2026
Geographic-area designations1,216——HRSA, 2026
Population-group designations968——HRSA, 2026

A systematic review of 144 studies with 90,189 participants found that stigma has a small-to-moderate negative effect on help-seeking (median d = −0.27) and ranks fourth among barriers, with disclosure concerns the most commonly reported stigma barrier (Clement et al., 2015). A meta-analysis of 27 studies found that people’s own negative attitudes toward help-seeking (OR 0.80) and stigmatising attitudes toward people with mental illness (OR 0.82) were associated with less active help-seeking, while perceived public stigma was not, with substantial between-study heterogeneity (I² 58% to 91%) (Schnyder et al., 2017). Across WHO World Mental Health surveys in 24 countries (n = 63,678), low perceived need was the most common reason for not initiating treatment, a desire to handle the problem on one’s own was the most common barrier among those who perceived a need (63.8%), and attitudinal barriers were much more important than structural ones overall, although attitudinal barriers dominated for mild-to-moderate cases and structural barriers for severe cases (Andrade et al., 2014).

These studies measure how strongly disclosure concerns, personal attitudes and a preference for self-reliance are associated with less help-seeking, and Clement et al. (2015) state that the findings can inform the design of interventions to increase help-seeking. They do not evaluate an entry point that requires no identity disclosure and supports self-directed learning, so whether such a design changes help-seeking remains open.

Method (Planned) Two-arm randomized comparison among adults seeking self-serve mental-wellness education, recruited online: each participant is randomly assigned to the wallet-signature entry or a name-and-email registration and completes the measures at entry and at four weeks, with the sample size set by an a priori power analysis. Stigma measures are administered anonymously in both arms, so the arms are designed to differ only in the entry method. Baseline BACE and ATSPPH-SF scores, age, gender, prior help-seeking and prior wallet use are recorded before randomization, and balance between arms is checked on each (standardized mean difference below 0.1).
Data and measures (Planned) Barriers to Access to Care Evaluation, including its treatment-stigma subscale (BACE; Clement et al., 2012); Attitudes Toward Seeking Professional Psychological Help, short form (ATSPPH-SF; Fischer & Farina, 1995); entry-flow completion logged as a system measure.
Analysis plan (Planned) Arm-by-time effects on BACE and ATSPPH-SF scores are tested with linear mixed-effects models adjusted for the baseline covariates (baseline score, age, gender, prior help-seeking, prior wallet use), analyzed by intention to treat, and entry-flow completion is compared between arms with logistic regression. Entry-flow completion is analyzed separately from the self-report measures.

Built component: Wallet-signature sign-in with a single-use nonce (EIP-191), with no name or email in sign-in: evidence.futuresystemslab.io (Connect Wallet)

Participant Autonomy and Data Sovereignty

Feeds: VALIDATE

Evidence

Given control over provider access, 45 of 105 participants (43%) restricted at least one provider, while 60 (57%) imposed no restrictions. Thirty-four (32.3%) blocked all personal information from all listed individuals of at least one provider or staff type. The share of individuals nationally who were offered and accessed their online medical records rose from 25% in 2014 to 65% in 2024.

Access restrictions chosen when people controlled provider access
Access restrictions chosen when people controlled provider access

Source: Schwartz et al., 2015, n = 105

View data
ItemValue95% CInSource
Blocked all personal information from all doctors, nurses and/or staff32.3%—105Schwartz et al., 2015
Blocked access by all doctors and/or nurses24.8%—105Schwartz et al., 2015
Denied access to all doctors, nurses and staff4.8%—105Schwartz et al., 2015
Individuals accessing their own online medical records
Individuals accessing their own online medical records

Source: Richwine, 2025 (ONC Data Brief No. 77), HINTS 2024, n = 7,278 (national survey; not peer-reviewed)

Survey-weighted national estimates; wave sizes: 2014 3,677 and 2020 3,865 (Westat, 2015, 2020); 2024 7,278.

View data
ItemValue95% CInSource
Offered and accessed online records, 201425%——ONC Data Brief No. 77 (2014)
Offered and accessed online records, 202465%——ONC Data Brief No. 77 (2024)
Accessed records by app (portal users), 202038%——ONC Data Brief No. 77 (2020)
Accessed records by app (portal users), 202457%——ONC Data Brief No. 77 (2024)

The GDPR sets principles for processing personal data, including limiting data to what is necessary (Art. 5), requires the controller to be able to demonstrate consent (Art. 7(1)), and gives the data subject the right to withdraw consent at any time, as easily as it was given (Art. 7(3)). Under HIPAA, an individual has a right of access to inspect and obtain a copy of protected health information in a designated record set, with exceptions that include psychotherapy notes (45 CFR § 164.524(a)(1)). Dynamic consent places a personalised digital interface between researchers and participants, letting individuals tailor and manage their own consent preferences and carry those preferences with their data (Kaye et al., 2015).

These instruments define participant rights to access, demonstrable consent and withdrawal, while the record of consent sits with the controller or covered entity. Dynamic consent has mainly been developed in biobanking, so participant-held, independently verifiable records of each grant and revocation for wellness data remain open.

Method (Planned) Within-subject comparison: adult participants complete a conventional consent form and a wallet-signed grant-and-revoke task in counterbalanced order and then complete the measures, while the system logs task success and time.
Data and measures (Planned) Quality of Informed Consent (QuIC; Joffe et al., 2001); System Usability Scale (SUS; Brooke, 1996); mHealth App Usability Questionnaire (MAUQ; Zhou et al., 2019); logged grant and revocation success and time to revoke.
Analysis plan (Planned) QuIC objective-understanding scores (0–100 scale) are tested for non-inferiority against a pre-specified margin of 5 points: the wallet-signature condition is non-inferior if the lower bound of the one-sided 97.5% confidence interval for the paired difference (wallet minus conventional) lies above −5 points, using a paired t-test, or a Wilcoxon signed-rank test with a Hodges–Lehmann interval where distributions require, with condition order included to check for carryover; SUS and MAUQ are reported descriptively, and revocation success as a proportion with a 95% confidence interval.

Built component: Participant-signed consent grants for each Sovereign Guide, with one-step revocation of every grant: evidence.futuresystemslab.io/security

Orthomolecular and Neurobiological Evidence

Feeds: VALIDATE

Evidence

The orthomolecular clinical literature (Walsh, Mensah, Hoffer and the Pfeiffer tradition) generated the hypotheses; meta-analyses reported statistically significant effects for EPA-predominant omega-3, methylfolate at 15 mg, vitamin D, zinc and N-acetylcysteine for depressive symptoms, of which Firth et al. (2019a) identify EPA-predominant omega-3 as the intervention with “the strongest evidentiary support” (SMD 0.61, reduced to 0.42 and still significant after adjusting for publication bias) and qualify the others (methylfolate only in few small trials; vitamin D and N-acetylcysteine with low confidence; zinc trials at high risk of attrition bias; “a lack of compelling evidence” for other vitamins, zinc, magnesium and inositol across mental disorders, with emerging evidence for vitamin D in major depression), alongside null results for DHA-predominant omega-3, folic acid, magnesium and inositol, a zinc deficit of 1.85 µmol/L in depression (Swardfager et al., 2013), and a placebo-controlled null result for adjuvant niacin (Ramsay et al., 1970); FSL’s participant-held longitudinal self-report is designed to test individual response.

Orthomolecular evidence map by evidence level and year
Orthomolecular evidence map by evidence level and year

Sources: 21 verified records, linked in the data table (PubMed, PMC, publisher and institute pages)

View data
SourceYearEvidence levelPeer-reviewedNote
Firth 2019a2019meta-analysisyesMeta-review of 33 meta-analyses of placebo-controlled RCTs (10,951 individuals)
Firth 2019b2019meta-analysisyesMeta-analysis of 16 RCTs of dietary improvement (corrected by 2020 and 2021 errata)
Busby 20182018meta-analysisyesSystematic review with meta-analysis: gluten-free diet and depressive symptoms in gluten-related disorders (13 prospective studies, 1,139 participants)
Sarris 20162016meta-analysisyesPositive replicated results for SAMe, methylfolate, omega-3 and vitamin D; mixed for zinc, folic acid, vitamin C, tryptophan; nonsignificant for inositol
Swardfager 20132013meta-analysisyesZinc 1.85 µmol/L lower in depression (95% CI 1.19-2.51)
Papakostas 20122012RCTyesTwo double-blind trials: 7.5 then 15 mg null (n = 148); 15 mg NNT about 6 (n = 75)
Ramsay 19701970RCTyesPlacebo-controlled comparative study (randomization not stated in the abstract): no significant difference for adjuvant nicotinic acid
Petrie 19811981RCTyesCMHA collaborative 48-week study (randomization not stated in the abstract): single vitamins significant, combination not
Walsh 19971997cohort/case-controlyesMedian Cu/Zn 1.40 in 135 assaultive males vs 1.02 in 18 controls
Yao 20062006cohort/case-controlyesHigher urinary isoprostane F2α-VI (oxidative stress) and platelet- and endothelial-activation markers in children with autism vs controls
Crayton 20072007cohort/case-controlyesSerum copper 131 vs 111 µg/dL with vs without post-partum depression history
Osmond 19621962case series/clinical databaseyesReview of a nine-year niacin study (level from title; outcomes not in the PubMed record)
Hoffer 19641964case series/clinical databaseyesTen-year follow-up of niacin treatment (level from title; outcomes not in the PubMed record)
Walsh 20042004case series/clinical databaseyes207 consecutive cases, uncontrolled; 92% of compliant assaultive cases reported fewer assaults
Faber 20092009case series/clinical databaseyesReview of prior records for 230 children with ASD; mean Zn/Cu 0.608
Hambly 20172017case series/clinical databaseyesOpen-label micronutrient trial, 31 completers, MOAS d = 1.26
Pfeiffer 19821982book/expert opinionyesReview: zinc, the brain and behavior
McGinnis 2008a2008book/expert opinionyesNarrative review, Discerning the Mauve Factor Part 1 (Altern Ther Health Med)
McGinnis 2008b2008book/expert opinionyesNarrative review, Part 2
Walsh 20122012book/expert opinionnoBook: Nutrient Power (Skyhorse)
Mensah 20192019book/expert opinionnoTownsend Letter article listed by Mensah Medical; no peer-reviewed Mensah paper found
Nutrient and diet effects on depressive and anxiety symptoms, by evidence level
Nutrient and diet effects on depressive and anxiety symptoms, by evidence level

Source: Firth et al., 2019a (33 meta-analyses, n = 10,951); Firth et al., 2019b (corrected values; 16 RCTs, n = 45,826)

Limitations: all zinc RCTs were rated at high risk of attrition bias; N-acetylcysteine heterogeneity was I² = 92.64%; Firth et al. (2019a) characterize the vitamin D evidence as emerging.

View data
ItemValue95% CInSource
Omega-3, MDD (13 RCTs)0.398 (SMD)0.114 to 0.6821,233Firth et al., 2019a
Omega-3 >50% EPA0.61 (SMD)0.38 to 0.85969Firth et al., 2019a
Omega-3 ≥50% DHA-0.028 (SMD)-0.21 to 0.16469Firth et al., 2019a
Folate-based adjunct0.37 (SMD)0.01 to 0.72904Firth et al., 2019a
Folic acid0.4 (SMD)-0.08 to 0.88657Firth et al., 2019a
Methylfolate 15 mg0.73 (SMD)0.28 to 1.1999Firth et al., 2019a
Methylfolate incl. 7.5 mg0.34 (SMD)-0.4 to 1.08249Firth et al., 2019a
Vitamin D0.58 (SMD)0.45 to 0.72948Firth et al., 2019a
Zinc, adjunct in MDD0.66 (SMD)0.26 to 1.06104Firth et al., 2019a
Magnesium0.22 (SMD)-0.17 to 0.48538Firth et al., 2019a
N-acetylcysteine0.37 (SMD)0.19 to 0.55574Firth et al., 2019a
Inositol0.35 (SMD)-0.2 to 0.89188Firth et al., 2019a
Dietary improvement, depression0.162 (g)0.055 to 0.26945,826 (16 RCTs)Firth et al., 2019b
Dietary improvement, anxiety0.085 (g)-0.031 to 0.2022,270 (11 RCTs)Firth et al., 2019b
Micronutrients and aggression: open-label trial without a control group
Micronutrients and aggression: open-label trial without a control group

Source: Hambly et al., 2017, 31 completers; within-group pre-post change in aggression (MOAS), not comparable with the controlled effects on depression and anxiety above

View data
ItemValue95% CInSource
Micronutrients, aggression (MOAS; open-label)1.26 (d)—31 completedHambly et al., 2017
Peripheral blood zinc in depression vs controls
Peripheral blood zinc in depression vs controls

Source: Swardfager et al., 2013, 17 studies, n = 1,643 depressed and 804 controls

View data
ItemValue95% CInSource
All studies-1.85 (WMD)-2.51 to -1.191,643 depressed; 804 controlsSwardfager et al., 2013
Inpatients-2.543 (WMD)-3.522 to -1.5641,643 depressed; 804 controls (review total)Swardfager et al., 2013
Community samples-0.943 (WMD)-1.563 to -0.3231,643 depressed; 804 controls (review total)Swardfager et al., 2013
Higher-quality studies-2.354 (WMD)-2.901 to -1.8071,643 depressed; 804 controls (review total)Swardfager et al., 2013

A meta-review of 33 meta-analyses (10,951 individuals) found the strongest evidence for polyunsaturated fatty acids, particularly eicosapentaenoic acid, as an adjunctive treatment for depression, positive effects of high-dose methylfolate in major depressive disorder, emergent evidence for N-acetylcysteine, and good safety profiles across supplements (Firth et al., 2019a). A systematic review found primarily positive results in replicated studies of adjunctive S-adenosylmethionine, methylfolate, omega-3 and vitamin D alongside antidepressants and mixed results for zinc, folic acid, vitamin C and tryptophan; of these, only omega-3 (a significant, moderate-to-strong effect) and folic acid (not significant) were meta-analyzed, with marked heterogeneity and funnel-plot asymmetry indicating potential study bias (Sarris et al., 2016). A meta-analysis of 16 randomized trials (45,826 participants; 15 of the 16 in samples with nonclinical depression) found that dietary interventions reduced depressive symptoms (g = 0.162, 95% CI 0.055 to 0.269, as corrected), with no effect on anxiety (Firth et al., 2019b; corrections: “The Effects of Dietary Improvement …: Erratum,” 2020; “…: Second Erratum,” 2021). In people with gluten-related disorders (mostly biopsy-proven celiac disease, plus celiac-antibody-positive adults and one cohort with diarrhea-predominant irritable bowel syndrome), depressive-symptom scores improved on a gluten-free diet (8 studies, 953 participants: one randomized trial and seven single-arm before-and-after studies; SMD −0.37, 95% CI −0.55 to −0.20), and in two crossover trials of people with self-reported non-celiac gluten sensitivity a blinded gluten challenge showed a nonsignificant trend toward worse depressive symptoms (p = 0.25); effects in people without a gluten-related disorder were not studied (Busby et al., 2018).

Meta-analyses reported statistically significant effects for some adjunctive nutrients and dietary improvement at population level, with marked heterogeneity between studies. Which individuals respond, which dietary components matter and how to deliver these interventions are open questions the authors themselves identify.

Method (Planned) Prospective observational cohort of adult participants using self-serve education, gated on IRB approval: participants log mood and nutrition in the app and complete the measures at baseline, 6 and 12 weeks.
Data and measures (Planned) PHQ-9 (Kroenke et al., 2001) and GAD-7 (Spitzer et al., 2006), administered only after IRB approval; participant mood and nutrition logs. Participant safety: any PHQ-9 item 9 response other than “Not at all” immediately displays the 988 Suicide & Crisis Lifeline (call or text 988 in the US) and emergency-services guidance, and alerts the study’s qualified clinician, who reviews it within one business day and offers the participant contact through the app under the IRB-approved risk-management procedure; each positive response and the action taken are logged and reported to the IRB.
Analysis plan (Planned) Mixed-effects growth models of PHQ-9 and GAD-7 scores with a random intercept and slope per participant estimate individual response alongside the group effect, adjusted for baseline symptom severity, age, medication use and baseline diet; the primary contrast is plant-based dietary change, and gluten-free adherence from the nutrition logs enters as a pre-specified exploratory moderator (interaction with plant-based change), reported as hypothesis-generating; the analysis is pre-registered before data collection.

Built component: Wallet-keyed participant mood and nutrition logs, readable only by the participant or a Sovereign Guide with an active grant: evidence.futuresystemslab.io/advisors/ghasemzadeh

Informatics and Interoperability

Feeds: VALIDATE

Evidence

Hospitals engaged in all four interoperability domains (send, receive, find and integrate) rose from 23% in 2014 to 76% in 2025.

Hospitals engaged in all four interoperability domains
Hospitals engaged in all four interoperability domains

Source: ONC Health IT Quick Stat #66, non-federal acute care hospitals (2020 survey reported as 2021; no 2024 value)

View data

HL7 FHIR Release 4 (v4.0.1) defines the Observation resource for measurements and simple assertions, and its Vital Signs profile codes heart rate as LOINC 8867-4. FHIR R4 also defines a Consent resource for recording a healthcare consumer’s choices. SMART on FHIR lets applications run unmodified across health record systems using contemporary web standards for transport, authorization and interface, and its authors report the need for pragmatic constraints on base FHIR (Mandel et al., 2016).

SMART on FHIR standardizes how applications reach data in electronic health record systems, and FHIR defines how consent is represented. How a participant’s own wallet-signed consent can govern FHIR data held outside those systems remains open.

Method (Planned) Conformance study: a fixed corpus of synthetic HL7v2 ORU^R01 messages and wearable readings runs through the bridge and the wearable route, and each output resource is validated and compared field by field with its source.
Data and measures (Planned) HL7 FHIR R4 validator results against the R4 Observation and Vital Signs profiles; data completeness rate (source fields present in the output); mapping fidelity rate (values, units and LOINC codes matching the source).
Analysis plan (Planned) Validation errors and warnings are counted per resource type, completeness and fidelity are reported as proportions with 95% confidence intervals, and every failure is traced to its mapping rule.

Built component: HL7v2 → FHIR R4 interface-engine bridge: evidence.futuresystemslab.io/hl7-fhir; Google Health → FHIR R4 wearable route: demo.futuresystemslab.io

Decentralized Architecture

Feeds: BUILD

Evidence

Of 65 papers in a systematic review of blockchain in healthcare, 45 were technical and 14 of those presented a proof-of-concept implementation.

Blockchain-in-healthcare papers: technical papers vs implementations
Blockchain-in-healthcare papers: technical papers vs implementations

Source: Agbo et al., 2019, 65 included papers

View data
ItemValue95% CInSource
Technical papers45—65 papersAgbo et al., 2019
Proof-of-concept implementations14—65 papersAgbo et al., 2019

A review for biomedical informatics sets out blockchain features, their benefits for health care applications compared with traditional distributed databases, current applications, and the challenges of adoption with proposed solutions (Kuo et al., 2017). A PRISMA systematic review found many proposed healthcare use cases for blockchain but a lack of adequate prototype implementations and of studies characterizing their effectiveness (Agbo et al., 2019). BIP-32 hierarchical deterministic wallets let account public extended keys be shared so that all incoming and outgoing transactions can be seen without exposing any secret key, the basis of a watch-only wallet.

The systematic review finds few working prototypes and little evaluation of effectiveness for healthcare uses of blockchain. A 2025 systematic review reports that adoption remains limited to conceptual work and proofs of concept, often on simulated datasets rather than validated real-world data (Shaikh et al., 2025). Evidence from deployed, measured systems operated by small practices therefore remains limited.

Method (Planned) Operational measurement over a fixed observation window on production infrastructure, using scripted test invoices settled in Bitcoin through the self-hosted BTCPay server and anchored record batches on the Ethereum Sepolia testnet.
Data and measures (Planned) Settlement correctness (recorded against BTCPay-settled invoices); anchoring latency (record creation to confirmed root) and cost (gas per batch and per record); verification success rate (records whose proof recomputes to the anchored root).
Analysis plan (Planned) Correctness and verification success are reported as proportions with 95% confidence intervals, and latency and cost as medians with interquartile ranges per batch size.

Built component: Self-hosted BTCPay settlement to a watch-only wallet, with record Merkle roots anchored to MerkleAnchor on the Ethereum Sepolia testnet: evidence.futuresystemslab.io/sovereign-clinical

Methods Matrix

StreamDesignSampleInstrumentsAnalysisStatus
Stigma and AccessTwo-arm randomized comparison of entry flowsAdults seeking self-serve mental-wellness education, recruited online; size set by an a priori power analysisBACE (Clement et al., 2012); ATSPPH-SF (Fischer & Farina, 1995), administered anonymously in both arms; entry-flow completionLinear mixed-effects models (arm × time), adjusted for baseline covariates, by intention to treat; logistic regression for entry-flow completionPlanned · IRB-gated
Participant Autonomy and Data SovereigntyWithin-subject comparison, counterbalancedAdult participantsQuIC (Joffe et al., 2001); SUS (Brooke, 1996); MAUQ (Zhou et al., 2019); logged grant and revocation success and timeNon-inferiority on QuIC (5-point margin; one-sided 97.5% CI) by paired t-test or Wilcoxon signed-rank with Hodges–Lehmann interval, condition order checked for carryover; SUS and MAUQ descriptive; revocation success as a proportion with 95% CIPlanned · IRB-gated
Privacy and ConsentFormal protocol verification; consent-text comprehensionSymbolic models of the EIP-191 and EIP-712 variants; adult participants for QuICTamarin (Meier et al., 2013) or ProVerif (Blanchet, 2001); QuIC (Joffe et al., 2001)Lemmas proved or refuted; counterexample traces with fix and re-verificationPlanned (verification) · IRB-gated (QuIC)
Orthomolecular and Neurobiological EvidenceProspective observational cohort (baseline, 6 and 12 weeks)Adult participants using self-serve educationPHQ-9 (Kroenke et al., 2001); GAD-7 (Spitzer et al., 2006); mood and nutrition logs, including gluten-free adherenceMixed-effects growth models adjusted for baseline severity, age, medication use and baseline diet; primary contrast plant-based dietary change; gluten-free adherence as a pre-specified exploratory moderator; pre-registeredPlanned · IRB-gated
Informatics and InteroperabilityConformance studyFixed corpus of synthetic HL7v2 messages and wearable readingsHL7 FHIR R4 validator (HL7 International, n.d.-b); completeness and fidelity ratesError and warning counts; proportions with 95% CIPlanned
Decentralized ArchitectureOperational measurement over a fixed windowScripted test invoices settled in Bitcoin through the self-hosted BTCPay server and anchored record batches on the Ethereum Sepolia testnetSettlement correctness; anchoring latency and cost; verification success rateProportions with 95% CI; medians with IQRPlanned

Ethics and Data Governance

Every human-participant study on this page is Planned and begins only after IRB approval. Any PHQ-9 item 9 response other than “Not at all” triggers the participant safety procedure in the orthomolecular study design. Platform sign-in collects a wallet address and a single-use nonce only. In the stigma study, the comparison arm registers with name and email, and study measures are administered anonymously in both arms. Consent is managed by the participant’s wallet: each grant or revocation of a single Sovereign Guide’s access is a participant wallet signature verified with a single-use nonce; the participant can also revoke every grant at once from the signed-in session, without a separate signature.

Research Limitations

Data collection from external participants begins after IRB approval; every study on this page is Planned. The work has a single evaluator to date. Several outcomes rely on self-report measures. The orthomolecular cohort is observational, which limits causal inference. A self-selected online sample limits generalizability. Formal verification covers the modeled protocol only. System limitations are documented under Known Limitations on the portfolio home page (https://evidence.futuresystemslab.io/#limitations), and security findings and controls on the security page. Participants in the wallet conditions will sign with standard (EOA) wallets, the signature type EncryptHealth verifies.

References

  1. Access of individuals to protected health information, 45 C.F.R. § 164.524. https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-C/part-164/subpart-E/section-164.524
  2. Agbo, C. C., Mahmoud, Q. H., & Eklund, J. M. (2019). Blockchain technology in healthcare: A systematic review. Healthcare, 7(2), Article 56. https://doi.org/10.3390/healthcare7020056
  3. Andrade, L. H., Alonso, J., Mneimneh, Z., Wells, J. E., Al-Hamzawi, A., Borges, G., Bromet, E., Bruffaerts, R., de Girolamo, G., de Graaf, R., Florescu, S., Gureje, O., Hinkov, H. R., Hu, C., Huang, Y., Hwang, I., Jin, R., Karam, E. G., Kovess-Masfety, V., . . . Kessler, R. C. (2014). Barriers to mental health treatment: Results from the WHO World Mental Health surveys. Psychological Medicine, 44(6), 1303–1317. https://doi.org/10.1017/S0033291713001943
  4. Blanchet, B. (2001). An efficient cryptographic protocol verifier based on Prolog rules. In Proceedings of the 14th IEEE Computer Security Foundations Workshop (pp. 82–96). IEEE. https://doi.org/10.1109/CSFW.2001.930138
  5. Bloemen, R., Logvinov, L., & Evans, J. (2017). EIP-712: Typed structured data hashing and signing [Ethereum Improvement Proposal]. https://eips.ethereum.org/EIPS/eip-712
  6. Brooke, J. (1996). SUS: A “quick and dirty” usability scale. In P. W. Jordan, B. Thomas, I. L. McClelland, & B. Weerdmeester (Eds.), Usability evaluation in industry (pp. 207–212). CRC Press. https://doi.org/10.1201/9781498710411-35
  7. Busby, E., Bold, J., Fellows, L., & Rostami, K. (2018). Mood disorders and gluten: It’s not all in your mind! A systematic review with meta-analysis. Nutrients, 10(11), Article 1708. https://doi.org/10.3390/nu10111708
  8. Chang, W., Rocco, G., Millegan, B., Johnson, N., & Terbu, O. (2021). EIP-4361: Sign-In with Ethereum [Ethereum Improvement Proposal]. https://eips.ethereum.org/EIPS/eip-4361
  9. Clement, S., Brohan, E., Jeffery, D., Henderson, C., Hatch, S. L., & Thornicroft, G. (2012). Development and psychometric properties the Barriers to Access to Care Evaluation scale (BACE) related to people with mental ill health. BMC Psychiatry, 12, Article 36. https://doi.org/10.1186/1471-244X-12-36
  10. Clement, S., Schauman, O., Graham, T., Maggioni, F., Evans-Lacko, S., Bezborodovs, N., Morgan, C., Rüsch, N., Brown, J. S. L., & Thornicroft, G. (2015). What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies. Psychological Medicine, 45(1), 11–27. https://doi.org/10.1017/S0033291714000129
  11. Crayton, J. W., & Walsh, W. J. (2007). Elevated serum copper levels in women with a history of post-partum depression. Journal of Trace Elements in Medicine and Biology, 21(1), 17–21. https://doi.org/10.1016/j.jtemb.2006.10.001
  12. The effects of dietary improvement on symptoms of depression and anxiety: A meta-analysis of randomized controlled trials: Erratum. (2020). Psychosomatic Medicine, 82(5), 536. https://doi.org/10.1097/PSY.0000000000000807
  13. The effects of dietary improvement on symptoms of depression and anxiety: A meta-analysis of randomized controlled trials: Second erratum. (2021). Psychosomatic Medicine, 83(2), 196. https://doi.org/10.1097/PSY.0000000000000914
  14. European Parliament and Council of the European Union. (2016). Regulation (EU) 2016/679 (General Data Protection Regulation). Official Journal of the European Union, L 119. https://eur-lex.europa.eu/eli/reg/2016/679/oj
  15. Faber, S., Zinn, G. M., Kern, J. C., II, & Kingston, H. M. (2009). The plasma zinc/serum copper ratio as a biomarker in children with autism spectrum disorders. Biomarkers, 14(3), 171–180. https://doi.org/10.1080/13547500902783747
  16. Firth, J., Marx, W., Dash, S., Carney, R., Teasdale, S. B., Solmi, M., Stubbs, B., Schuch, F. B., Carvalho, A. F., Jacka, F., & Sarris, J. (2019b). The effects of dietary improvement on symptoms of depression and anxiety: A meta-analysis of randomized controlled trials. Psychosomatic Medicine, 81(3), 265–280. https://doi.org/10.1097/PSY.0000000000000673
  17. Firth, J., Teasdale, S. B., Allott, K., Siskind, D., Marx, W., Cotter, J., Veronese, N., Schuch, F., Smith, L., Solmi, M., Carvalho, A. F., Vancampfort, D., Berk, M., Stubbs, B., & Sarris, J. (2019a). The efficacy and safety of nutrient supplements in the treatment of mental disorders: A meta-review of meta-analyses of randomized controlled trials. World Psychiatry, 18(3), 308–324. https://doi.org/10.1002/wps.20672
  18. Fischer, E. H., & Farina, A. (1995). Attitudes Toward Seeking Professional Psychological Help Scale—Short Form [Database record]. APA PsycTests. https://doi.org/10.1037/t05375-000
  19. Hambly, J. L., Francis, K., Khan, S., Gibbons, K. S., Walsh, W. J., Lambert, B., Testa, C., & Haywood, A. (2017). Micronutrient therapy for violent and aggressive male youth: An open-label trial. Journal of Child and Adolescent Psychopharmacology, 27(9), 823–832. https://doi.org/10.1089/cap.2016.0199
  20. Health Resources and Services Administration. (2026). Designated health professional shortage areas statistics: Third quarter of fiscal year 2026, as of June 30, 2026. U.S. Department of Health and Human Services. https://data.hrsa.gov/Default/GenerateHPSAQuarterlyReport
  21. HL7 International. (n.d.-a). HL7 FHIR Release 4 (v4.0.1). Retrieved September 29, 2026, from https://hl7.org/fhir/R4/
  22. HL7 International. (n.d.-b). Validation: FHIR v4.0.1. Retrieved September 29, 2026, from https://hl7.org/fhir/R4/validation.html
  23. Hoffer, A., & Osmond, H. (1964). Treatment of schizophrenia with nicotinic acid: A ten year follow-up. Acta Psychiatrica Scandinavica, 40(2), 171–189. https://doi.org/10.1111/j.1600-0447.1964.tb05744.x
  24. Joffe, S., Cook, E. F., Cleary, P. D., Clark, J. W., & Weeks, J. C. (2001). Quality of informed consent: A new measure of understanding among research subjects. Journal of the National Cancer Institute, 93(2), 139–147. https://doi.org/10.1093/jnci/93.2.139
  25. Kaye, J., Whitley, E. A., Lund, D., Morrison, M., Teare, H., & Melham, K. (2015). Dynamic consent: A patient interface for twenty-first century research networks. European Journal of Human Genetics, 23(2), 141–146. https://doi.org/10.1038/ejhg.2014.71
  26. Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x
  27. Kuo, T.-T., Kim, H.-E., & Ohno-Machado, L. (2017). Blockchain distributed ledger technologies for biomedical and health care applications. Journal of the American Medical Informatics Association, 24(6), 1211–1220. https://doi.org/10.1093/jamia/ocx068
  28. Mandel, J. C., Kreda, D. A., Mandl, K. D., Kohane, I. S., & Ramoni, R. B. (2016). SMART on FHIR: A standards-based, interoperable apps platform for electronic health records. Journal of the American Medical Informatics Association, 23(5), 899–908. https://doi.org/10.1093/jamia/ocv189
  29. McGinnis, W. R., Audhya, T., Walsh, W. J., Jackson, J. A., McLaren-Howard, J., Lewis, A., Lauda, P. H., Bibus, D. M., Jurnak, F., Lietha, R., & Hoffer, A. (2008a). Discerning the mauve factor, Part 1. Alternative Therapies in Health and Medicine, 14(2), 40–50. https://pubmed.ncbi.nlm.nih.gov/18383989/
  30. McGinnis, W. R., Audhya, T., Walsh, W. J., Jackson, J. A., McLaren-Howard, J., Lewis, A., Lauda, P. H., Bibus, D. M., Jurnak, F., Lietha, R., & Hoffer, A. (2008b). Discerning the mauve factor, Part 2. Alternative Therapies in Health and Medicine, 14(3), 56–62. https://pubmed.ncbi.nlm.nih.gov/18517107/
  31. Meier, S., Schmidt, B., Cremers, C., & Basin, D. (2013). The TAMARIN prover for the symbolic analysis of security protocols. In N. Sharygina & H. Veith (Eds.), Computer aided verification (pp. 696–701). Springer. https://doi.org/10.1007/978-3-642-39799-8_48
  32. Mensah, A. (2019). The new paradigm for cognitive health. Townsend Letter, (246). Listed at https://mensahmedical.com/research/
  33. Office for Civil Rights, U.S. Department of Health and Human Services. (n.d.). Breach portal [Data set]. Retrieved September 30, 2026, from https://ocrportal.hhs.gov/ocr/breach/breach_report.jsf
  34. Office for Civil Rights, U.S. Department of Health and Human Services. (2026). Annual report to Congress on breaches of unsecured protected health information for calendar year 2024. https://www.hhs.gov/sites/default/files/breach-report-to-congress-2024.pdf
  35. Office of the National Coordinator for Health Information Technology. (2026). Electronic health information exchange by hospitals (Health IT Quick Stat #66). https://healthit.gov/data/quickstats/electronic-health-information-exchange-hospitals/
  36. Osmond, H., & Hoffer, A. (1962). Massive niacin treatment in schizophrenia: Review of a nine-year study. The Lancet, 279(7224), 316–320. https://doi.org/10.1016/s0140-6736(62)91259-x
  37. Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., Baer, L., Dalton, E. D., Sacco, G. R., Schoenfeld, D., Pencina, M., Meisner, A., Bottiglieri, T., Nelson, E., Mischoulon, D., Alpert, J. E., Barbee, J. G., Zisook, S., & Fava, M. (2012). L-methylfolate as adjunctive therapy for SSRI-resistant major depression: Results of two randomized, double-blind, parallel-sequential trials. American Journal of Psychiatry, 169(12), 1267–1274. https://doi.org/10.1176/appi.ajp.2012.11071114
  38. Petrie, W. M., Ban, T. A., & Ananth, J. V. (1981). The use of nicotinic acid and pyridoxine in the treatment of schizophrenia. International Pharmacopsychiatry, 16(4), 245–250. https://doi.org/10.1159/000468501
  39. Pfeiffer, C. C., & Braverman, E. R. (1982). Zinc, the brain and behavior. Biological Psychiatry, 17(4), 513–532. https://pubmed.ncbi.nlm.nih.gov/7082716/
  40. Ramsay, R. A., Ban, T. A., Lehmann, H. E., Saxena, B. M., & Bennett, J. (1970). Nicotinic acid as adjuvant therapy in newly admitted schizophrenic patients. Canadian Medical Association Journal, 102(9), 939–942. https://pmc.ncbi.nlm.nih.gov/articles/PMC1946733/
  41. Richwine, C. (2025). Individuals’ access and use of patient portals and smartphone health apps, 2024 (Data Brief No. 77). Office of the Assistant Secretary for Technology Policy. https://healthit.gov/data/data-briefs/individuals-access-and-use-patient-portals-and-smartphone-health-apps-2024/
  42. Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., & Ng, C. H. (2016). Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. American Journal of Psychiatry, 173(6), 575–587. https://doi.org/10.1176/appi.ajp.2016.15091228
  43. Schnyder, N., Panczak, R., Groth, N., & Schultze-Lutter, F. (2017). Association between mental health-related stigma and active help-seeking: Systematic review and meta-analysis. British Journal of Psychiatry, 210(4), 261–268. https://doi.org/10.1192/bjp.bp.116.189464
  44. Schwartz, P. H., Caine, K., Alpert, S. A., Meslin, E. M., Carroll, A. E., & Tierney, W. M. (2015). Patient preferences in controlling access to their electronic health records: A prospective cohort study in primary care. Journal of General Internal Medicine, 30(Suppl. 1), S25–S30. https://doi.org/10.1007/s11606-014-3054-z
  45. Shaikh, M., Memon, S. A., Ebrahimi, A., & Wiil, U. K. (2025). A systematic literature review for blockchain-based healthcare implementations. Healthcare, 13(9), Article 1087. https://doi.org/10.3390/healthcare13091087
  46. Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. https://doi.org/10.1001/archinte.166.10.1092
  47. Swardfager, W., Herrmann, N., Mazereeuw, G., Goldberger, K., Harimoto, T., & Lanctôt, K. L. (2013). Zinc in depression: A meta-analysis. Biological Psychiatry, 74(12), 872–878. https://doi.org/10.1016/j.biopsych.2013.05.008
  48. Swende, M. H., & Johnson, N. (2016). EIP-191: Signed data standard [Ethereum Improvement Proposal]. https://eips.ethereum.org/EIPS/eip-191
  49. Tam, N. T., Huy, N. T., Thoa, L. T. B., Long, N. P., Trang, N. T. H., Hirayama, K., & Karbwang, J. (2015). Participants’ understanding of informed consent in clinical trials over three decades: Systematic review and meta-analysis. Bulletin of the World Health Organization, 93(3), 186–198H. https://doi.org/10.2471/BLT.14.141390
  50. Walsh, W. J. (2012). Nutrient power: Heal your biochemistry and heal your brain. Skyhorse Publishing. https://openlibrary.org/isbn/9781620872581
  51. Walsh, W. J., Glab, L. B., & Haakenson, M. L. (2004). Reduced violent behavior following biochemical therapy. Physiology & Behavior, 82(5), 835–839. https://doi.org/10.1016/j.physbeh.2004.06.023
  52. Walsh, W. J., Isaacson, H. R., Rehman, F., & Hall, A. (1997). Elevated blood copper/zinc ratios in assaultive young males. Physiology & Behavior, 62(2), 327–329. https://doi.org/10.1016/s0031-9384(97)88988-3
  53. Westat. (2015). Health Information National Trends Survey 4 (HINTS 4) cycle 4 methodology report. National Cancer Institute. https://hints.cancer.gov/docs/HINTS_4_Cycle_4_Methodology_Report.pdf
  54. Westat. (2020). Health Information National Trends Survey 5 (HINTS 5) cycle 4 methodology report. National Cancer Institute. https://hints.cancer.gov/docs/methodologyreports/HINTS5_Cycle4_MethodologyReport.pdf
  55. Wuille, P. (2012). BIP-32: Hierarchical deterministic wallets [Bitcoin Improvement Proposal]. https://github.com/bitcoin/bips/blob/master/bip-0032.mediawiki
  56. Yao, Y., Walsh, W. J., McGinnis, W. R., & Praticò, D. (2006). Altered vascular phenotype in autism: Correlation with oxidative stress. Archives of Neurology, 63(8), 1161–1164. https://doi.org/10.1001/archneur.63.8.1161
  57. Zhou, L., Bao, J., Setiawan, I. M. A., Saptono, A., & Parmanto, B. (2019). The mHealth App Usability Questionnaire (MAUQ): Development and validation study. JMIR mHealth and uHealth, 7(4), Article e11500. https://doi.org/10.2196/11500